TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07164469: Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma

Sponsor: M.D. Anderson Cancer Center · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 100 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07164469 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07164469 Rescue Dossier →